ABSTRACT
FEN1 has key roles in Okazaki fragment maturation during replication, long patch base excision repair, rescue of stalled replication forks, maintenance of telomere stability and apoptosis. FEN1 may be dysregulated in breast and ovarian cancers and have clinicopathological significance in patients. We comprehensively investigated FEN1 mRNA expression in multiple cohorts of breast cancer [training set (128) ) and multivariate analysis (p= 9.19 x 10 -7 ). At the protein level, in ER positive tumours , FEN1 overexpression remains significantly linked to high grade, high mitotic index and pleomorphism (ps<0.01).
In ER negative tumours, high FEN1 is significantly associated with pleomorphism, tumour type, lymphovascular invasion, triple negative phenotype, EGFR and HER2 expression (ps<0.05). In ER positive as well as in ER negative tumours, FEN1 protein overexpression is associated with poor survival in univariate and multivariate analysis (ps<0.01). In ovarian epithelial cancers, similarly, FEN1 overexpression is associated with high grade, high stage and poor survival (ps<0.05). We conclude that FEN1 is a promising biomarker in breast and ovarian epithelial cancer.
INTRODUCTION
The flap structure specific endonuclease (FEN1) is critical for processing DNA intermediates generated during DNA long patch base excision repair (LP-BER) and Okazaki fragment maturation during replication. FEN1 is also essential for rescue of stalled replication forks, maintenance of telomere stability and apoptotic fragmentation of DNA (Shen et al., 2005; Zheng et al., 2011) . FEN1 belongs to XPG/RAD2 endonuclease family and FEN1 gene is located at 11q22. FEN1 possesses flap endonuclease, 5' exonuclease and gap-endonuclease activities to accomplish its various biological functions. FEN1 is subjected to posttranslational modifications such as acetylation, phosphorylation, sumoylation, methylation and ubiquitylation that regulate nuclease activities as well as protein-protein interactions and sub-cellular compartmentalization (Shen et al., 2005; Zheng et al., 2011) .
FEN1 may have a role in carcinogenesis. A tumour suppressor function for FEN1 has been
shown in preclinical models (Henneke et al., 2003a; Henneke et al., 2003b; Kucherlapati et al., 2007; Kucherlapati et al., 2002; Wu et al., 2012; Xu et al., 2011) . Whereas, FEN1
homologous knock out in mice is embryonically lethal FEN1 heterozygous mice are viable (Larsen et al., 2003) . A double heterozygous mouse model with a mutation in FEN1 and adenomatous polyposis coli (APC) gene displayed enhanced cancer development and poor survival (Kucherlapati et al., 2007) . In addition, a FEN1 E160D mutant mouse model displayed altered DNA repair as well as apoptotic DNA fragmentation and associated with increased mutation frequency and cancer development (Larsen et al., 2008; Zheng et al., 2007) . In human studies, polymorphic variants of FEN1 may be associated with increased cancer susceptibility (Liu et al., 2012; Yang et al., 2009) . In established tumours, preclinical evidence suggests that FEN1 over expression may promote cancer progression and survival (Kim, 1998; Kim et al., 2005; Krause et al., 2005; Sato et al., 2003) . Proliferating cells consistently over express FEN1 compared to quiescent cells (Kim, 1998) . In pro-myelocytic leukemia cells (HL-60), FEN1 gene expression was shown to be higher during mitotic phase compared to the resting phase of the cell cycle and FEN1 expression markedly decreased upon induction of terminal differentiation in cells (Kim, 1998) . FEN1 mRNA over expression has also been demonstrated in lung cancer cell lines (Sato et al., 2003) and gastric cancer cell lines (Kim et al., 2005) . In human tumours, frequent overexpression of FEN1 has been reported (Singh et al., 2008) . In a small cohort of 50 breast tumours, FEN1 was shown to be upregulated in tumours compared to normal tissue in that study (Singh et al., 2008) .
However, clinicopathological significance of FEN1 upregulation remains unknown in breast and ovarian cancer (Singh et al., 2008) .
We hypothesised that FEN1 may be dysregulated in human breast and ovarian cancer, contributing to the aetiology of the disease. We investigated FEN1 mRNA as well as FEN1
protein expression in large cohorts of breast and ovarian tumours and correlated to clinicopathological variables and outcome data. In the current study we demonstrate that FEN1 overexpression is associated with aggressive phenotype and poor survival in breast and ovarian cancer. The data provides evidence that FEN1 is a promising biomarker.
MATERIALS AND METHODS

FEN1 gene expression (training set):
The study population used was derived from the information. Gene expression profiling has been previously described (Chin et al., 2007) .
Briefly, total RNA was extracted from a series of frozen breast cancers retrieved from
Nottingham Hospitals NHS Trust Tumour Bank between 1986 and 1992. RNA integrity and DNA contamination were analysed using Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). Total RNA was biotin-labelled using the Illumina TotalPrep RNA Amplification kit (Ambion, Austin, TX, USA) according to manufacturer's instructions.
Biotin-labelled cRNA (1.5 µg) was used for each hybridisation on Sentrix Human-6
BeadChips (Illumina, San Diego, CA, USA) in accordance with the manufacturer's protocol.
Illumina gene expression data containing 47,293 transcripts were analysed and summarised in the Illumina Bead Studio software. Analyses of the probe level data were done using the beadarray Bioconductor package. The expression data are available at the EBI website (http://www.ebi.ac.uk/miamexpress/) with the accession number E-TABM-576.
FEN1 gene expression (Test Set):
The Uppsala cohort originally composed of 315 women representing 65% of all breast cancers resected in Uppsala County, Sweden, from January 1, 1987 , to December 31, 1989 . Demographics are summarized in supplementary Table S2 of supporting information and also described elsewhere (Bergh et al., 1995) . Tumour samples were microarray profiled on the Affymetrix U133A&B genechips. Microarray analysis was carried out at the Genome Institute of Singapore. All microarray data are accessible at National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/). Data can be accessed via series accession number (GSE4922). RNA preparation, microarray hybridization, and data processing were carried out essentially as described (Pawitan et al., 2005) . All data were normalized using the global mean method (MAS5), and probe set signal intensities were natural log transformed and scaled by adjusting the mean signal to a target value of log 500.
FEN1 gene expression (external validation):
External validation was performed in the METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) cohort. The METABRIC study protocol, detailing the molecular profiling methodology in a cohort of 1980 breast cancer samples is described by Curtis et al (Curtis et al., 2012 HT-12 v3 platform. The data was pre-processed and normalized as described previously (Curtis et al.) . FEN1 expression was investigated in this data set. The Chi-square test was used for testing association between categorical variables and a multivariate Cox model was fitted to the data using as endpoint breast cancer specific death. Recursive partitioning (Hothorn et al., 2006) was used to identify a cut-off in gene expression values such that the resulting subgroups have significantly different survival courses.
FEN1 protein expression in breast cancer:
The study was performed in a consecutive series of 1650 patients with primary invasive breast carcinomas who were diagnosed between 1986 and 1999 and entered into the Nottingham Tenovus Primary Breast Carcinoma series.
All patients were treated uniformly in a single institution and have been investigated in a wide range of biomarker studies (Abdel-Fatah et al., 2013b; Abdel-Fatah et al., 2013c; Abdel-Fatah et al., 2014a; Abdel-Fatah et al., 2014b; Sultana et al., 2013) .
Clinicopathological characteristics of ER negative cohort is summarized in Supplementary Statistical analysis: Data analysis was performed using SPSS (SPSS, version 17 Chicago, IL). Where appropriate, Pearson's Chi-square, Fisher's exact, Student's t and ANOVA one way tests were used. Cumulative survival probabilities were estimated using the KaplanMeier method, and differences between survival rates were tested for significance using the log-rank test. Multivariate analysis for survival was performed using the Cox proportional hazard model. The proportional hazards assumption was tested using standard log-log plots.
Hazard ratios (HR) and 95% confidence intervals (95% CI) were estimated for each variable.
All tests were two-sided with a 95% CI and a p value < 0.05 considered significant. For multiple comparisons, p values were adjusted according to Holm-Bonferroni correction method.
Cell lines and culture:
To evaluate the specificity of the FEN1 antibody used in the current study FEN1 deficient and proficient cells were investigated. FEN1 deficient HeLa SilenciX® cells and control FEN1 proficient HeLa SilenciX® cells were purchased from Tebu-Bio (www.tebu-bio.com). SilenciX cells were grown in DMEM medium (with L-Glutamine 580mg/L, 4500 mg/L D19 Glucose, with 110mg/L Sodium Pyruvate) supplemented with 10% FBS, 1% penicillin/streptomycin and 125 μg/ml Hygromycin B. Western blot analysis was performed as described previously (Sultana et al., 2013) . Table S4 ). High FEN1 mRNA expression in tumours was also associated with adverse disease specific survival in patients (p=0.008) (Figure 1a ). In the test set (n=249), 50.2% of tumours had high FEN1 mRNA expression, which remained associated with high T-stage (p=0.007), lymph node positivity (p=0.012), high grade (p<0.0001), high molecular grade (p<0.0001), mutant p53 (p<0.0001) and ER negativity (p=0.001) (Supplementary Table S5 ). High FEN1 mRNA expression in tumours was associated with adverse disease specific survival in patients (p=0.00009) (Figure 1b (Curtis et al.) . We investigated whether FEN1 mRNA expression would associate with these distinct biological subgroups. High FEN1 mRNA expression was significantly associated with intClust.1 (p<0.0001), intClust.5 (p<0.0001), intClust.9 (p<0.0001) and intClust.10 (p<0.0001), which had the worst clinical outcome in the METABRIC study (Curtis et al.) . Low FEN1 mRNA expression was associated with intClust.3 (p<0.0001), intClust.4 (p<0.0001), intClust.7 (p=0.003) and intClust.8 (p<0.0001), which had intermediate to good prognosis in the METABRIC study (Curtis et al.) . High FEN1 mRNA expression in tumours was associated with adverse disease specific survival in the whole cohort (p<0.0001) (Figure 1c ). In multivariate Cox regression analysis that included other validated prognostic factors, such as lymph node stage, histological grade and tumour size (NPI components), FEN1 mRNA expression was a powerful independent predictor for clinical outcome (p<0.0001) ( Table 2) . Moreover, in patients who received adjuvant endocrine therapy (n=1199), high FEN1 mRNA expression remained significantly associated with adverse disease specific survival (p<0.0001) (Figure 1d ). In patients who received adjuvant chemotherapy (n=413), high FEN1 mRNA expression was likewise associated with adverse disease specific survival (p=0.019) (Figure 1e ).
RESULTS
High
FEN1 mRNA expression analysis in the training set, test set and in the external validation cohort provides confirmatory evidence that high FEN1 mRNA expression is associated with adverse clinicopathological features, aggressive molecular phenotypes and poor survival in patients.
FEN1 protein expression is linked to aggressive breast cancer and poor survival
As the multifunctional roles of FEN1 are likely regulated by several mechanisms, including sub-cellular compartmentalization between, for example, the nucleus and cytoplasm/mitochondria, we proceeded to evaluate FEN1 protein expression in independent cohorts of 568 ER negative breast tumours and 894 ER positive breast tumours.
Clinicopathological characteristics are summarized in supplementary Tables S6 and S7 .
Treatment data is summarized in supplementary treatment data 1. We also correlated FEN1 protein expression to other biomarkers of aggressive phenotype (ER, PR, EGFR, CK14, CK5/6, CK17, CK18, HER2) and DNA repair (PARP1, BRCA1, ATM, XRCC1 and TOP2A). Antigens, primary antibodies, clone, source, optimal dilution and scoring system for each immunohistochemical marker are summarized in supplementary Table S8 .
We first confirmed the specificity of FEN1 antibody used in the current study. As shown in figure 2a1 , FEN1 proficient cell line shows robust FEN1 protein expression whereas FEN1 knockdown cell shows almost complete absence of FEN1 protein expression. We then conducted immunohistochemical investigations. In 568 ER negative tumours (Figure 2a2) Table   S9 ). High nuclear/high cytoplasmic FEN1 expression was associated with poor survival (p=0.003) (Figure 2b ). In patients with early stage lymph node negative (low risk) tumours who did not receive adjuvant chemotherapy, high nuclear/high cytoplasmic tumours remained significantly associated with poor survival (p=0.009) (Figure 2c ). In patients who received CMF (cyclophosphamide, methotrexate and 5-Fluoruracil) chemotherapy, high nuclear/high cytoplasmic was associated with poor survival (p=0.05) (Figure 2d ). The group that received anthracycline adjuvant chemotherapy did not reach significance (p=0.211), although there was a trend toward poor survival in high nuclear/low cytoplasmic tumours (Supplementary Figure S1a) . In the multivariate COX model, FEN1 expression is independently associated with breast cancer specific survival (p=0.007), as well as progression free survival (p=0.003) ( Table 3) .
In 894 ER positive breast tumours, we similarly found significant association between FEN1 expression and tumour size (p= 0.004), grade (p<0.0001), pleomorphism (p= 0.0004), tumour type (p<0.0001), tubule formation (p<0.0001) and lymphovascular invasion (p=0.007). FEN1
expression was also associated with other DNA repair factors, such as BRCA1 (p= 0.003), XRCC1 (p<0.0001), ATM (p<0.0001) and TOP2A (p<0.0001) (Full data is summarized in supplementary Table S10 ). High cytoplasmic/low nuclear FEN1 tumours were associated with poor survival (p=0.00016) in ER positive tumours (Figure 2e ). In patients with early stage lymph node negative (low risk) tumours who did not receive adjuvant tamoxifen, high cytoplasmic/low nuclear FEN1 tumours remained significantly associated with poor survival (p=0.003) (Supplementary Figure S1b) . In patients with high risk tumours who did not receive adjuvant tamoxifen, high cytoplasmic/low nuclear FEN1 is associated with poor survival (p=0.026) (Figure 2f ). On the other hand, patients with tumours that had low cytoplasmic/low nuclear FEN1 had better survival implying that these tumours could be spared long term adjuvant endocrine therapy. In patients with high risk tumours who received adjuvant tamoxifen, high cytoplasmic/low nuclear FEN1 was associated with poor survival (p=0.003) (Figure 2g ). On the other hand, patients with tumours that had high cytoplasmic/high nuclear FEN1 had better survival implying that FEN1 could be predictive biomarker of response to endocrine therapy. In the multivariate COX model, FEN1
expression was independently associated with breast cancer specific survival (p=0.003), as well as progression free survival (p=0.004) ( Table 3) .
Taken together, the FEN1 mRNA expression as well as FEN1 protein expression data provides compelling evidence that FEN1 expression is a prognostic and a predictive biomarker in breast cancer.
FEN1 protein expression is linked to aggressive epithelial ovarian cancer and poor survival
We then proceeded to investigate the significance of FEN1 protein expression in 156 ovarian epithelial cancers. Demographics are summarized in supplementary Investigating nuclear as well cytoplasmic expression together, we found that high cytoplasmic/high nuclear FEN1 tumours had the worst ovarian cancer specific (p=0.006) ( Figure 3b ) and disease free (p=0.008) ( Figure 3c ). Taken together, the data provides evidence that FEN1 overexpression is a promising biomarker in ovarian epithelial cancers.
DISCUSSIONS
This is the largest and the first comprehensive study to evaluate FEN1 in breast and ovarian cancers. In breast cancer, high FEN1 mRNA is linked to aggressive features such as high grade, high mitotic index, pleomorphism, de-differentiation, PAM50. Her2 and PAM50.
basal molecular phenotypes. FEN1 is essential for the repair of oxidative base damage through long-patch base excision repair. The data presented here suggests that high FEN1 mRNA expression is an adaptive response to oxidative stress that is common in breast cancer cells (Brown and Bicknell, 2001) . Although not fully understood, a recent study suggested FEN1 promoter hypomethylation as a mechanism for FEN1 mRNA over expression in tumours (Singh et al., 2008) . High FEN1 mRNA seen in tumours with high mitotic index also concurs with previous studies demonstrating FEN1 upregulation in cycling cells (Kim, 1998; Kim et al., 2005; Krause et al., 2005; Sato et al., 2003) . In the current study, we have also provided the first evidence that FEN1 mRNA levels are linked to biologically distinct integrative clusters reported in the METABRIC study (Curtis et al., 2012) . High FEN1 mRNA level was frequent in intClust 10 subgroup which is the most highly genomically instable sub group with basal-like features. Interestingly, low FEN1 mRNA level was seen in intClust 3 subgroup that is characterised by low genomic instability. Together the data provides evidence that high FEN1 mRNA could be utilised as a biomarker of genomic instability in human tumours. In addition, high FEN1 mRNA level is also frequently seen in intClust 5 (HER-2 enriched with worst survival), intClust 9 (8q cis-acting/20qamplified mixed subgroup), and intClust 1 (17q23/20q cis-acting luminal B subgroup) subgroups that also manifest an aggressive phenotype. On the other hand, low FEN1 mRNA level is linked to intClust 4 (includes both ER-positive and ER-negative cases with a flat copy number landscape and termed the 'CNA-devoid' subgroup with extensive lymphocytic infiltration), intClust 7 (16p gain/16q loss with higher frequencies of 8q amplification luminal A subgroup) and intClust 8 subgroups (classical 1q gain/16q loss luminal A subgroup) (Curtis et al., 2012) . The data implies differential roles for FEN1 in distinct molecular phenotypes of breast cancer. High FEN1 mRNA is associated with poor survival in univariate as well as in multivariate analyses in the whole cohort which is likely to be related to the aggressive phenotype described previously. As expected, intClust 10, intClust 9, intClust 5 and intClust 1 sub-groups that are associated with high FEN1 levels were also associated with poor prognosis in METABRIC study (Curtis et al., 2012) . On the other hand, intClust 3, intClust 4, intClust 7 and intClust 8 that are associated with low FEN1 expression, are associated with good to intermediate prognosis (Curtis et al., 2012) . Together, the data provides conclusive evidence that FEN1 mRNA level has prognostic significance in breast cancer. To investigate if FEN1 mRNA expression may also have predictive significance, we conducted sub-group analysis in tumours treated with adjuvant chemotherapy or endocrine therapy. In patients treated with endocrine therapy, we provide the first evidence that high FEN1 mRNA level is associated with poor survival implying resistance to endocrine therapy. The link between FEN1, oestrogen and oestrogen receptors (ER) are beginning to emerge. FEN1 not only interacts directly with ER-α but can also augment the interaction of ER-α with oestrogen response element containing DNA and impact upon estrogen-responsive gene expression in cells (Buterin et al., 2006; Moggs et al., 2005) . Our data suggests that FEN1 mRNA over expression is a novel biomarker for endocrine resistance and is likely related to the role of FEN1 in cell proliferation. We have also demonstrated for the first time that high FEN1 mRNA level is associated with poor survival in patients who received adjuvant chemotherapy implying resistance to cytotoxic therapy.
We then investigated FEN1 protein expression immunohistochemicaly in large cohorts of breast cancers. Although strong association between FEN1 mRNA level and high tumour grade as well as high mitotic index was evident, FEN1 protein level analysis revealed a complex association in breast cancer. In the ER positive cohort, grade 3 and higher mitotic index tumours were more likely in low nuclear/high cytoplasmic FEN1 tumours compared to high nuclear/low cytoplasmic FEN1 or high nuclear/high cytoplasmic FEN1 tumours.
Surprisingly, grade 3 and high mitotic index tumours were also seen frequently in low nuclear/low cytoplasmic FEN1 tumours in the ER positive cohort. In ER positive tumours cytoplasmic over expression correlated to poor survival. In ER negative tumours, although no significant clinicopathological associations were seen, high nuclear FEN1 was associated with poor survival. A limitation of our study is that it is retrospective and prospective studies will be needed to confirm our observation. Given the complex multifunctional role of FEN1
protein that is likely regulated by sub-cellular compartmentalization and post-translational modification mechanisms, our data suggest that detailed preclinical mechanistic studies will be required to evaluate the roles of FEN1 protein in breast cancer pathogenesis. However, it is important to note that the clinical data presented here is consistent with a recent preclinical study where FEN1 knockdown by siRNA was shown to be associated with reduced cellular proliferation (van Pel et al., 2013) . Moreover, treatment with specific FEN1 inhibitors isolated in that study also resulted in reduced proliferation in cells (van Pel et al., 2013) . In another preclinical study, FEN1 mRNA depletion by siRNA resulted in increased sensitivity to chemotherapy such as alkylating agents and platinum chemotherapy (Nikolova et al., 2009 ). Taken together the data suggest that FEN1 mRNA levels are likely to be the best predictors of response to chemotherapy or endocrine therapy in breast cancer.
Interestingly, FEN1 protein expression also linked to other DNA repair factors such as BRCA1, PARP1, XRCC1 and TOP2A implying altered genomic stability in breast tumours.
In contrast to ER negative tumours, in ER positive tumours we found an association between high FEN1 and ATM expression. Previous studies indicate a functional link between FEN1
and ER. FEN1 may regulate ER induced transcriptional response by enhancing the interaction of ER with oestrogen response elements-containing DNA (Schultz- Norton et al., 2007) . Interestingly a recent study suggests that ER may be involved in the regulation of ATM expression (Guo et al., 2013) . In light of the preclinical evidence presented above, the clinical data presented here suggest a complex network that may be operating between ER, FEN1 and ATM in breast cancer cells. However, detailed mechanistic studies are required to confirm this hypothesis.
In ovarian cancer, similarly, FEN1 expression is linked to aggressive phenotype and poor survival. Recently, we investigated FEN1 in gastric cancers (Abdel-Fatah et al., 2013a) . FEN1 protein over expression was associated with high T-stage (p=0.005), lymph node-positive disease (p=0.02) and poor disease specific survival (p=0.006) (Abdel-Fatah et al., 2013a) . In another study in prostate cancer, FEN1 protein over expression was associated with aggressive disease (Lam et al., 2006) . Taken together the data suggest that FEN1 protein expression has prognostic and predictive significance in cancers.
Our clinical data suggests that FEN1 may be a promising drug target in cancer. Interestingly, a recent study extrapolating yeast genetic interaction data has also identified FEN1 as an attractive anti-cancer target (van Pel et al., 2013) . We have recently initiated a FEN1 drug discovery programme. To facilitate the search for novel FEN1 inhibitors, we developed a fluorogenic donor/quencher reporter pair to monitor generation of reaction product in real time (Dorjsuren et al., 2011 In conclusion, the data presented in the current clinical study suggests that FEN1 is promising biomarker in breast and ovarian epithelial cancers. 
